Lungs News and Research

RSS

No overall cancer risk in people who donate stem cells

American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

7 Dec 2010

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.

7 Dec 2010

Screening for CCDC40 gene mutations may help determine risk for congenital heart defects

A gene that can cause congenital heart defects has been identified by a team of scientists, including a group from Princeton University. The discovery could lead to new treatments for those affected by the conditions brought on by the birth defect.

7 Dec 2010

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

At the prestigious annual British Thoracic Society meeting in London on December 1st, Dr Caroline Baxter reported the highly sensitive performance of Myconostica's real-time PCR assay MycAssayTM Aspergillus in cystic fibrosis sputum which is 260% more sensitive than the currently used culture.

6 Dec 2010

New research focusing on VTE presented at ASH Annual Meeting

The latest advances in the treatment of bleeding and clotting disorders will be presented today at the 52nd Annual Meeting of the American Society of Hematology, focusing on venous thrombeombolism, a potentially life-threatening disorder in which abnormal blood clots form in the veins and restrict the flow of blood. New studies examine risk-prediction models and cutting-edge treatment options for patients with VTE.

6 Dec 2010

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Red blood cells have the very important role of carrying oxygen from the lungs to the rest of the body; therefore, disorders that affect RBCs can have a significant impact on quality of life. Sickle cell disease and malaria are two common RBC diseases that affect a significant portion of the U.S. and global populations. Sickle cell disease, a genetic blood disorder that causes deformed and dysfunctional red blood cells, affects an estimated 70,000 to 100,000 Americans, while malaria affects approximately 1,500 Americans annually and 190 to 311 million people worldwide.

6 Dec 2010

Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Monthly blood transfusions combined with daily medication to remove the resulting excess iron remains the best approach for reducing the risk of recurrent strokes in young patients with sickle cell anemia, according to a preliminary analysis of a multicenter trial that includes St. Jude Children's Research Hospital.

6 Dec 2010

Patients with H1N1 flu die due to over-reactive immune response: Research

On November 19, Jason Martin returned to the Medical Intensive Care Unit at Vanderbilt University Medical Center for the first time since he nearly died there during last year's H1N1 flu pandemic. The tall and burly Warren County, TN, ambulance worker - a 30-year-old, father of three young children - broke down and hugged some of the nurses he recognized.

6 Dec 2010

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Results from four innovative studies help answer outstanding questions about stem cell transplant procedures in treating various hematologic malignancies. Research that will be presented today at the 52nd Annual Meeting of the American Society of Hematology reveals that there is no increase in overall cancer risk in people who donate stem cells and that the utilization of a double cord blood stem cell transplant is associated with better overall outcomes when used early in the treatment of acute leukemias.

6 Dec 2010

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

ImmunoGen, Inc., a biotechnology company that develops antibody-based anticancer products, today announced the presentation of positive initial clinical data with the Company's IMGN901 anticancer compound when used as part of a standard combination regimen to treat relapsed multiple myeloma.

6 Dec 2010

Companies, media organizations join Georgia Prostate Cancer Coalition to launch pledge campaign

Prostate cancer is a serious health concern in Georgia. According to the American Cancer Society, the state of Georgia ranks 11th in number of estimated deaths per capita from the disease. In an effort to raise awareness about prostate cancer and ensure more men commit to be informed and screened, several companies and media organizations have joined the Georgia Prostate Cancer Coalition in launching a pledge campaign.

4 Dec 2010

Music benefits patients on mechanical ventilation

The benefits of listening to music for patients on mechanical ventilation was revealed in a systematic review by a team of Cochrane researchers led by Drexel University College of Nursing and Health Professions associate professor Dr. Joke Bradt. The review found that listening to music may relax patients and potentially result in fewer complications.

4 Dec 2010

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

A newly published study in the Lancet suggested that a first-line treatment regimen including Zometa (zoledronic acid) significantly improved overall survival and progression-free survival in newly diagnosed multiple myeloma patients compared with a regimen that included oral clodronate. The impact on survival was independent of the effect of Zometa on bone complications (also known as skeletal-related events or SREs).

4 Dec 2010

Research findings could provide breakthrough for development of effective therapies for NSCLC

Research at Virginia Commonwealth University Massey Cancer Center led by Charles E. Chalfant, Ph.D., associate professor of biochemistry and molecular Biology, discovered a previously unknown mechanism in non-small cell lung cancer cells that contributes to their ability to maintain and grow tumors. Narrowing in on this mechanism could provide a breakthrough for the development of effective therapies for NSCLC and other cancers.

4 Dec 2010

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Exposure to polluted air early in life led to an accumulation of abdominal fat and insulin resistance in mice even if they ate a normal diet, according to new research.

3 Dec 2010

Sagent launches chemotherapy agent topotecan hydrochloride for injection

Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced U.S. FDA approval and launch of its topotecan hydrochloride for injection, a chemotherapy agent, in conjunction with the innovator's patent expiry. Sagent's topotecan is available in 4 mg single-dose latex-free vials.

3 Dec 2010

BMEYE signs licensing agreement with PULSION Medical Systems

BMEYE's Breakthrough Totally Noninvasive Blood Pressure and Cardiac Output Technology Will be Incorporated Into PULSION's Next Generation Patient Monitors

3 Dec 2010

New approach to biomarker detection for early lung cancer diagnosis

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are biomarkers of disease state.

2 Dec 2010

CAIRE enters definitive agreement to acquire SeQual

Chart Industries, Inc. announced that its wholly-owned subsidiary, CAIRE Inc., which operates under its BioMedical segment, has entered into a definitive agreement to acquire SeQual Technologies Inc. for approximately $40 million, plus the possibility of up to $20 million of additional future payments contingent on SeQual's financial performance over a two-year period post-closing.

From CAIRE Inc 2 Dec 2010

NHS to develop new treatment options for patients with lung disease

Scientists and clinicians in Nottingham are to work more closely with industry to develop new ways of diagnosing and treating lung disease.

2 Dec 2010

Lungs News and Research

No overall cancer risk in people who donate stem cells

Champions Biotechnology, Pharmaceutical Industries sign Master Service Agreement

Screening for CCDC40 gene mutations may help determine risk for congenital heart defects

Performance of Myconostica's MycAssay Aspergillus in CF reported at British Thoracic Society meeting

New research focusing on VTE presented at ASH Annual Meeting

Research highlighting treatment for pediatric SCD, malaria presented at ASH 2010

Study compares efficacy of two treatments for iron overload caused by chronic transfusion therapy

Patients with H1N1 flu die due to over-reactive immune response: Research

New studies answer questions related to stem cell transplant procedures in treating hematologic malignancies

Positive initial clinical data of IMGN901 used in combination regimen for multiple myeloma presented at ASH Annual Meeting

Companies, media organizations join Georgia Prostate Cancer Coalition to launch pledge campaign

Music benefits patients on mechanical ventilation

Zometa improves OS, PFS in newly diagnosed multiple myeloma patients: Phase III study

Research findings could provide breakthrough for development of effective therapies for NSCLC

Exposure to polluted air leads to accumulation of abdominal fat and insulin resistance

Sagent launches chemotherapy agent topotecan hydrochloride for injection

BMEYE signs licensing agreement with PULSION Medical Systems

New approach to biomarker detection for early lung cancer diagnosis

CAIRE enters definitive agreement to acquire SeQual

NHS to develop new treatment options for patients with lung disease

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News